clinical trial · NCT06639607
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastomaEpendymomaPEP-CMV vaccineTetanus boosterNivolumabTemozolomide
brief summary
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
started
Aug 31, 2026
primary completion
Aug 31, 2031
completion
Jun 30, 2051
last updated
Jul 20, 2026
official title
Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol